GMO? On Thu, Apr 1, 2021 at 12:27 PM Hiers, David <[email protected]> wrote:
> No AI here... This is classic, small-batch, hand-crafted, free-range, > organic, gluten-free content. > > > David > > > -----Original Message----- > From: VoiceOps <[email protected]> On Behalf Of Alex Balashov > Sent: Thursday, April 1, 2021 12:18 PM > To: Brandon Svec <[email protected]> > Cc: [email protected] > Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ > > Let me make sure I understand your question correctly: it is your belief > or conjecture that this press release was automatically generated by a > machine learning system? > > — > Sent from mobile, with due apologies for brevity and errors. > > > On Apr 1, 2021, at 3:10 PM, Brandon Svec <[email protected]> > wrote: > > > > GPT-3? Happy April Fools Day. > > > > Brandon > > > >> On Mar 31, 2021, at 9:47 PM, Alex Balashov <[email protected]> > wrote: > >> > >> For immediate release: > >> > >> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership > >> with Posner | Palner Pharmaceuticals, are pleased to announce the > >> eagerly anticipated start of Phase III clinical trials of Kamailio > >> DMQ module replication. > >> > >> In this stage of the investigation of the promising replication > >> scheme, which was developed in record time, DMQ will be tested in a > >> rigourous, double-blind, controlled CI/CD process for large-scale > >> efficacy and continually monitored for safety in shorter and longer > terms. > >> > >> The now-concluded second phase established basic safety and Phase 2b > >> entailed a dose-finding study for the optimal number of batched > >> `dmq_usrloc` contacts per kilogram of cloud computing resource. > >> > >> The main cohort of the main sequence of the Phase III trial will > >> enroll 380 randomly selected, statistically representative Floridian > >> SIP registrars and > >> 5700 SIP dialogs, also in the state of Florida. When asked about the > >> disparity in the number of registrars versus dialogs, Alex Balashov > >> of Evariste said, "It is reflective of the small number of SIP > >> registrars in Florida; not to be indelicate, but consider the median > age of the population." > >> > >> As previously remarked upon in proceedings of the World SIP > >> Organisation (WSO), the choice of Florida as a venue attracted some > >> questions. We asked Fred Posner of Posner | Palner about the clinical > >> background informing this choice of replication study cohort: > >> > >> "Florida is a good place to find eventual consistency failures; the > >> open climate and reluctance to accept traditional data integrity > >> science would have sealed the deal, but when people started to drink > >> bleach here, I saw an opportunity." > >> > >> Evariste and Posner | Palner are aiming for a US Food & Drug > >> Administration EUA (Emergency Use Authorisation) for DMQ replication > >> as a prophylactic data redundancy and failover measure to ward off > >> the development of moderate to severe viral Sonus Haemorrhagic Fever > symptoms. > >> > >> Phase II studies have painted a promising a picture of the DMQ > >> architecture's ability to reduce moderate to severe symptoms and > >> associated 28-day mortality by more than 90%, albeit over a small > >> sample size and in enterprise patients with known pre-existing > >> comorbidities such as Session Border Controller and BroadSoft > >> Multi-System Inflammatory Syndrome. Phase III trials seek to bolster > >> quantums of broader efficacy, including efficacy for localised > outbreaks of small to medium business softswitch. > >> > >> Of the control group, Balashov said, "They will receive a standard > >> pipe-to-/dev/null placebo protocol, but with identical '200 OK' > >> confirmation messages. We proudly developed this approach in early > >> 2020 in consultation with the highest levels of the Trump > >> presidential administration; it is called TENP, or 'The Emperor's New > >> Potion.' It is a successor to that administration's previous approved > placebo protocol, SHTI - Small Hands, Tremendous Initiatives." > >> > >> Despite speculative autism and packet fragmentation claims by Florida > >> Governor Ron DeSantis, Balashov was quick to provide reassurance > >> about side effects from DMQ in the Phase III trial. > >> > >> "The incidence of severe allergies to plain-text UDP was within > >> standard deviation over the mean for all insecure replication, and > >> there's support for other transports on the way. Anyway, we have a > >> robust adverse effects reporting system in our issue tracker and > >> solid surveillance. Don't let partisan politics dissuade you from > allowing request lines with the KDMQ method." > >> > >> Other industry sources have reported that DMQ is not the only > >> replication investigation undertaken by Evariste and Posner | Palner, > >> although it is the only prophylactic suitable for the early infection > >> development and inflammatory phases of a broad class of SBC-complex > >> syndromes typically afflicting service providers. A recent IETF > >> preprint by the same authors has shown high-quality preliminary data > >> suggesting statistically significant improvement in morbidity > >> outcomes from Perimeta and Nokia via a later-stage therapeutic > intervention with a monoclonal, monorepo Github cocktail administered > intravenously. > >> > >> > >> -- > >> Alex Balashov | Principal | Evariste Systems LLC > >> > >> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free) > >> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/ > >> _______________________________________________ > >> VoiceOps mailing list > >> [email protected] > >> https://puck.nether.net/mailman/listinfo/voiceops > _______________________________________________ > VoiceOps mailing list > [email protected] > https://puck.nether.net/mailman/listinfo/voiceops > > ---------------------------------------------------------------------- > This message and any attachments are intended only for the use of the > addressee and may contain information that is privileged and confidential. > If the reader of the message is not the intended recipient or an authorized > representative of the intended recipient, you are hereby notified that any > dissemination of this communication is strictly prohibited. If you have > received this communication in error, notify the sender immediately by > return email and delete the message and any attachments from your system. > _______________________________________________ > VoiceOps mailing list > [email protected] > https://puck.nether.net/mailman/listinfo/voiceops >
_______________________________________________ VoiceOps mailing list [email protected] https://puck.nether.net/mailman/listinfo/voiceops
